Trial Profile

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of AF-130 in Healthy Subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AF 130 (Primary)
Indications Hypertension; Migraine
Focus Adverse reactions
Sponsors Afferent Pharmaceuticals

Most Recent Events

27 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.
18 May 2016 According to a Afferent Pharmaceuticals media release, status changed from recruiting to completed.
11 Dec 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com